Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.64 |
| ▸ | MAOA | P21397 | 2/20 | 0.55 |
| ▸ | KDM1A | O60341 | 2/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.55 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | QDPR | P09417 | 1/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.47 |
| ▸ | HTR3B | O95264 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2800981 | 0.98 | HTR2C (0.65) | HTR2CMAOAKDM1AMAOBSIGMAR1 | |
| SCHEMBL16874642 | 0.93 | HTR2C (0.57) | HTR2CMAOAKDM1AMAOBSIGMAR1 | |
| SCHEMBL29891550 | 0.93 | HTR2C (0.57) | HTR2CMAOAKDM1AMAOBSIGMAR1 | |
| SCHEMBL6159027 | 0.90 | HTR2C (0.54) | HTR2CMAOAKDM1AMAOBSIGMAR1 | |
| SCHEMBL28488068 | 0.89 | HTR3A (0.59) | HTR2CMAOAKDM1AMAOBTDP1 | |
| SCHEMBL3552712 | 0.89 | HTR3A (0.59) | HTR2CMAOAKDM1AMAOBTDP1 | |
| Hydrochloric Acid SCHEMBL2268492 | 0.87 | HTR3A (0.58) | HTR2CMAOAKDM1AMAOBTDP1 | |
| SCHEMBL1515026 | 0.85 | DRD2 (0.59) | MAOAKDM1AMAOBMEN1KMT2A | |
| SCHEMBL5584716 | 0.84 | HTR2C (0.69) | HTR2CMAOAKDM1AMAOBSIGMAR1 | |
| SCHEMBL24629539 | 0.81 | HTR2C (0.46) | HTR2CMAOAKDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 369 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083722-A1 | BIFUNCTIONAL DEGRADERS COMPRISING ELECTROPHILIC PROTACS THAT ENGAGE DCAF1 AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | SCRIPPS RESEARCH INST (US) | 2026-03-26 | — | — | US | claimed |
| WO-2023225625-A2 | BIFUNCTIONAL DEGRADERS COMPRISING ELECTROPHILIC PROTACS THAT ENGAGE DCAF1 AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-11-23 | — | — | WO | claimed |
| EP-0630887-B1 | 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists | ZENECA LTD (GB) | 1999-07-28 | — | — | EP | claimed |
| US-5654299-A | TREATING RESPIRATORY SYSTEM DISORDER (I.E. ASTHMA) WITH NEUROKININ 2 RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1997-08-05 | — | — | US | claimed |
| EP-0630887-A1 | 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists | ZENECA LIMITED (GB) | 1994-12-28 | — | — | EP | claimed |
| US-12636290-B2 | BET inhibitors for modulating DUX4 expression in FSHD | SAINT LOUIS UNIVERSITY (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4731223-A1 | MORPHOLINE AND 1,4-OXAZEPANE COMPOUNDS AND ITS USE IN THERAPY | Universitat De Barcelona (ES) | 2026-04-29 | — | — | EP | disclosed |
| US-20260083722-A1 | BIFUNCTIONAL DEGRADERS COMPRISING ELECTROPHILIC PROTACS THAT ENGAGE DCAF1 AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | SCRIPPS RESEARCH INST (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CENTAURUS THERAPEUTICS (US) | 2026-03-12 | — | — | US | disclosed |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2025-11-25 | — | — | US | disclosed |
| US-12479816-B2 | 20-HETE formation inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| EP-0272208-B1 | AROMATICALLY SUBSTITUTED AZACYCLO-ALKYLALKANEDIPHOSPHONIC ACIDS | CIBA-GEIGY AG (CH) | 1991-06-12 | — | — | EP | disclosed |
| US-4871720-A | Aromatically substituted azacycloalkyl-alkanediphosphonic acids useful for the treatment of illnesses that can be attributed to calcium metabolism disorders | CIBA-GEIGY CORPORATION (US) | 1989-10-03 | — | — | US | disclosed |
| EP-0272208-A1 | Aromatically substituted azacyclo-alkylalkanediphosphonic acids | CIBA-GEIGY AG (CH) | 1988-06-22 | — | — | EP | disclosed |
| EP-0126480-B1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES, METHOD FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1988-01-20 | — | — | EP | disclosed |
| US-4559403-A | FOR TREATMENT OF CEREBRAL AND CARDIAC ISCHEMIAS | HOFFMANN-LA ROCHE INC. (US) | 1985-12-17 | — | — | US | disclosed |
| US-4544657-A | ANTISCHEMIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1985-10-01 | — | — | US | disclosed |
| EP-0126480-A1 | Substituted isoquinoline derivatives, method for their preparation, and pharmaceutical compositions containing these compounds | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-11-28 | — | — | EP | disclosed |
| US-4206117-A | Pyridinyl aminoalkyl ethers | BASF AKTIENGESELLSCHAFT (DE) | 1980-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083722-A1 | BIFUNCTIONAL DEGRADERS COMPRISING ELECTROPHILIC PROTACS THAT ENGAGE DCAF1 AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | DCAF1, MDM2, ADRM1 | HTR2C 1140/4885MAOA 2746/4885KDM1A 482/4885 |
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CERS2, DEGS1, CERT1 | HTR2C 3014/4885MAOA 4088/4885KDM1A 1851/4885 |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | HTR2C 751/4885MAOA 1306/4885KDM1A 1642/4885 |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DGKK, DGKG, DGKA | HTR2C 4530/4885MAOA 4125/4885KDM1A 1683/4885 |
| US-12479816-B2 | 20-HETE formation inhibitors | CYP4A22, ALOX5, ALOX15 | HTR2C 235/4885MAOA 123/4885KDM1A 3640/4885 |
| US-12636290-B2 | BET inhibitors for modulating DUX4 expression in FSHD | BRDT, BET1, PHKB | HTR2C 4055/4885MAOA 4087/4885KDM1A 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.